Chemoprevention of carcinoma prostate: A review

International Urology and Nephrology

Volumn 34, Issue 2, 2002, Pages 207-214

  Ansari, M S ^a   Gupta, N P ^a   Hemal, A K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BETA CAROTENE; CALCITRIOL; FENRETINIDE; FLUTAMIDE; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; RETINOL; RETINOL DERIVATIVE; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR; TUMOR MARKER; VITAMIN D; VITAMIN D DERIVATIVE;

CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CARCINOGENESIS; CLINICAL TRIAL; DIET RESTRICTION; DISEASE MARKER; DRUG EFFICACY; EVALUATION; FAT INTAKE; HIGH RISK PATIENT; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; MALE; MEDICAL LITERATURE; NONHUMAN; NUTRITION; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; SIDE EFFECT; TEA; VITAMIN INTAKE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOPREVENTION; DIET, ATHEROGENIC; DIETARY SUPPLEMENTS; HUMANS; MALE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0037879352     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023297725004     Document Type: Review

References (42)

1. Albanes D, Heinonen OP, Huttunen JK et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the alpha-Tocopherol Bet-Carotene Cancer Prevention. Am J Clin Nutr 1995; 62 (Suppl): 1427S.
2. Alberts SR, Blute ML. Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia. Urology 2001; 57 (4 Suppl 1): 188-190.
3. Ashish M Kamat, Donald L Lamm. Chemoprevention of urological cancer. J Urol 1999; 161: 1748-1760.
4. Benedict WF, Jones PA. Inhibition of transformation and oncologic progression by ascorbic acid: A possible role in chemoprevention. In: Arnot MS, van Eys J, Wang YM, eds, Molecular Interrelations of Nutrition and Cancer. New York: Raven Press, 1982: 351.
5. Boone CW, Kelloff GJ. Biomarker end-points in cancer chemoprevention trials. IARC Sci Publ 1997; 142: 273-280.
6. Boone CW, Bacus JW, Bacus JV et al. Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials. Proc Soc Exp Biol Med 1997; 216(2): 151-165.
7. Bosland MC. Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Eur Urol 1999; 35(5-6): 459-463.
8. Bostwick DG. Prostatic intraepithelial neoplasia is a risk factor for cancer. Semin Urol Oncol 1999; 17(4): 187-198.
9. Bostwick DG, Montironi R, Sesterhenn IA. Diagnosis of prostatic intraepithelial neoplasia: Prostate Working Group/consensus report. Scand J Urol Nephrol Suppl 2000; 205: 3-10.
10. Brooks JD, Weinstein M, Lin X et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 1998; 7.
11. Diaz GD, Paraskeva C, Thomas MG et al. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy. Cancer Res 2000; 60(8): 2304-2312.
12. Eilchholzer M, Stahelin HB, Gey KF et al. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 1996; 66: 145.
13. Gupta S, Ahmad N, Mohan RR et al. Prostate cancer chemoprevention by green tea: In vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res 1999; 59(9): 2115-2120.
14. Gupta S, Ahmad N, Marengo SR et al. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAM mice. Cancer Res 2000; 60(18): 5125-5133.
15. Homma Y, Kaneko M, Kondo Y et al. Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143. J Natl Cancer Inst 1997; 89(11): 803-807.
16. Karmali RA. Eicosonoids in neoplasia. Prev Med 1987; 16: 493.
17. Khaff A, Schantz SP, Al-Rawi M et al. Green tea regulates cell cycle progression in oral leukoplakia. Head Neck 1998; 20(6): 528-534.
18. Van Der Kwast TH. Intermediate biomarkers for chemoprevention of prostate cancer. IARC Sci Publ 2001; 154: 199-205.
19. Lew EA, Garfinkel. Variations in mortality by weight among 750,000 men and women. J Chron Dis 1979; 32: 563.
20. Lokshin A, Zhang H, Mayotte J et al. Early effects of retinoic acid on proliferation, differentiation and apoptosis in non-small cell lung cancer cell lines. Anticancer Res 1999; 19(6B): 5251-5254.
21. Lopaczynski W, Hruszkewycz AM, Lieberman R. Preprostatectomy: A clinical model to study stromal-epithelial interactions. Urology 2001; 57 (4 Suppl 1): 194-199.
22. Marmag C, Menon M, Balaji KC et al. Effects of vitamin C on the prostate cancer cells in vitro: Effect on cell number, viability, and DNA synthesis. Prostate 1997; 32: 188.
23. Marshall JR. High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research. IARC Sci Publ 2001; 154: 191-198.
24. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995; 1(9): 997-1003.
25. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition 2000; 16(11-12): 1084-1089.
26. Nomura AM, Klonel LN, Hankin JH, Youshizava CN. Dietary factors in cancer of the lower urinary tract. Int J Cancer 1991; 48: 199.
27. Rao KV, Johnson WD, Bosland MC et al. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res 1999; 59(13): 3084-3089.
28. Rose DP. Dietary fatty acids and prevention of hormone responsive cancer. Proc Soc Exp Biol Med 1997; 216: 224.
29. Rose DP, Boyer AP, Wyner EI. International comparisons of mortality rates for cancer of the breast, ovary, prostate and colon, and per capita food consumption. Cancer 1986; 58: 2363.
30. Sakr WA, Partin AW. Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. Urology 2001; 57 (4 Suppl 1): 115-120.
31. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer (Hypothesis)? Anticancer Res 1990; 10: 1307.
32. Schwartz GG, Wang MH, Zang M et al. Alpha,25-Dihydroxyvitamin D (calciferol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomark Prev 1997; 6: 727.
33. Skowronski RJ, Peehl DM, Feldman D. Vitamin and prostate cancer: 1,25-dihydrovitamin D3 receptors and actions in human prostate cancer lines. Endocrinology 1993; 132: 152.
34. Slawin K, Kadmon D, Park SH et al. Dietary fenrethinide, a synthetic retinoid, decreases the tumor incidence and tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res 1993; 53: 4461.
35. Sun SY, Yue P, Mao L et al. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res 2000; 6(4): 1563-1573.
36. The alpha-Tocopherol Bet-Carotene Cancer Prevention Study. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. New Engl J Med 1994; 330: 1029.
37. Webber MM, Waghray A. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin Cancer Res 1995; 1(7): 755-761.
38. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications. Prostate 1997; 30(2): 136-142.
39. Webber MM, Quader ST, Kelinman HK et al. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 2001; 47(1): 1-13.
40. Willet WC, Polk BF, Morris JS et al. Prediagnostic serum selenium and risk of cancer. Lancet 1983; 2: 130.
41. Xie W, Wong YC, Tsao SW. Correlation of increased apoptosis and proliferation with development of prostatic intraepithelial neoplasia (PIN) in ventral prostate of the Noble rat. Prostate 2000; 44(1): 31-39.
42. Zhu W, Smith A, Young CY. A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology 1999; 140(11): 5451-5454.